Dr Reddy's, Sun Pharma and Hetero lead the push as companies eye opportunities in Latin America, Africa and other emerging markets
Dr Reddy's Laboratories has said the US health regulator classified the inspection outcome of its formulations manufacturing facility here as 'Voluntary Action Indicated (VAI)' and officially closed the inspection. In a regulatory filing on Saturday, the company said the Good Manufacturing Practices (GMP) inspection was conducted by the USFDA at its formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad. The company had earlier informed the stock exchanges regarding the inspection on August 14, 2026. "We wish to inform you that the United States Food and Drug Administration (USFDA) has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3)," Dr Reddy's said in the filing.
Brazil has 16.6 million adults aged between 20 and 79 living with diabetes, and ranks sixth globally in terms of the number of adults living with diabetes
The approval allows toripalimab with cisplatin and paclitaxel as first-line treatment for unresectable advanced, recurrent or metastatic ESCC in adults
Dr Reddy's Laboratories on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab), through which it aims to expand access to first-line immunotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) in India. The drug has been approved in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC, the pharma company said in a release. This marks Zytorvi's second approved indication in the country, expanding beyond nasopharyngeal carcinoma. ESCC accounts for approximately 80 per cent of all esophageal cancer cases in India, the company said. Zytorvi contains toripalimab, a monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, thereby supporting T-cell activity against cancer cells. The approval is supported by results from the Phase 3 JUPITER-06 trial. In the study, toripalimab in .
The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.
Initial QDENGA doses for India to come from Germany; private-market launch planned in H1 2027
The deal comes months after India's drug regulator approved Qdenga for use in both children and adults, making it the first dengue vaccine cleared for the country
India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy
North America weakness, lower margins, uncertainty over key launches weigh on earnings outlook
The drugmaker attributed the sharp earnings decline to a one-time semaglutide provision and the end of its lenalidomide agreement, while retaining its FY27 guidance
The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.
Dr Reddy's Foundation -- a family-owned trust and one of the key beneficiaries of the CSR funds of pharma major Dr Reddy's Laboratories -- is scaling up operations at its Hyderabad soil testing facility with the lab targeting between 75,000 and 1,00,000 samples ahead of the next Rabi season -- more than double what it processed in its first full year of operations. The move comes amid growing concern over depleting soil health and implementation gaps in the Centre's Soil Health Card scheme rolled out nationally in 2015. "Though the government's soil testing ecosystem exists, the scale of the problem is huge. So we decided to address this issue in our own way," said Suman Saraswathibatla, Director (Rural Livelihoods and Climate Action) at the foundation. This soil testing facility is central to the Foundation's broader soil health and regenerative agriculture programme, under which assessing soil condition is treated as the starting point for any intervention. The push for an in-hou
The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API used in the product
Drugmaker says it will supply 6-7 million pens in the last two quarters of FY27 and restart production by November after resolving the API-related quality issue
USFDA completed a pre-license inspection of the Hyderabad facility and issued a Form 483 with seven observations, which the company said it will address within the stipulated timeline
The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable efficacy and safety to the innovator drug
Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally
Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. "The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said. He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. "As GLP-1
The fall was driven by weak US sales of Revlimid, offset only partially by growth in India, Europe, and emerging markets